Letko, Brosseau & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Letko, Brosseau & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$173K	Hold	40,050	–	–	﹤0.01%	102
2026 Q2	$321K	Buy	40,050 +15,350	+62%	+$132K	﹤0.01%	93
2026 Q1	$198K	Hold	24,700	–	–	﹤0.01%	92
2025 Q4	$288K	Hold	24,700	–	–	﹤0.01%	86
2025 Q3	$248K	Hold	24,700	–	–	﹤0.01%	88
2025 Q2	$431K	Hold	24,700	–	–	0.01%	76
2025 Q1	$311K	Hold	24,700	–	–	0.01%	76
2024 Q4	$261K	Hold	24,700	–	–	0.01%	89
2024 Q3	$358K	Hold	24,700	–	–	0.01%	88
2024 Q2	$210K	Sell	24,700 -11,300	-31%	-$100K	﹤0.01%	93
2024 Q1	$368K	Hold	36,000	–	–	0.01%	87
2023 Q4	$197K	Hold	36,000	–	–	﹤0.01%	88
2023 Q3	$136K	Buy	+36,000	New	+$236K	﹤0.01%	90

Other funds holding SPRY

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Creek Drive Management Group San Francisco, California $368M AUM 23.05% 1-Year Est. Return

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return

Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Letko, Brosseau & Associates's SPRY Position: Q3 2026 in Review

Letko, Brosseau & Associates held its ARS Pharmaceuticals (SPRY) position steady in Q3 2026 at 40,050 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

Letko, Brosseau & Associates first reported a position in SPRY in Q3 2023 and has held it in 13 quarters since. The position peaked at $431K in Q2 2025. 88 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Letko, Brosseau & Associates held 40,050 shares of ARS Pharmaceuticals worth $173K as of Q3 2026.
Letko, Brosseau & Associates left its ARS Pharmaceuticals share count unchanged in Q3 2026.
ARS Pharmaceuticals made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q3 2026, its #102 holding.
Letko, Brosseau & Associates first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
Letko, Brosseau & Associates's ARS Pharmaceuticals position peaked at $431K in Q2 2025.
88 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q3 2026, filed 6 Nov 2026.